Citing MDx Reimbursement Changes, NeoGenomics Reports Flat Q2 Revenues | GenomeWeb

NEW YORK (GenomeWeb News) – Cancer genetics diagnostic company NeoGenomics today reported flat revenues for the second quarter, as changes to Medicare's reimbursement for molecular diagnostics negatively impacted operations.

The Fort Myers, Fla.-based company said that revenues for the three months ended June 30 totaled $15.6 million, the same as a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.